Regenxbio inc. (RGNX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-102,543

-94,733

-63,963

-48,581

-36,530

99,937

79,634

78,130

53,063

-73,169

-76,780

-74,228

-74,192

-62,967

-48,535

-37,715

-29,568

-22,811

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense

29,153

26,854

24,865

22,186

19,068

16,641

14,551

12,803

11,305

10,605

9,809

8,903

8,076

7,031

5,893

5,412

4,391

2,921

0

0

0

Net amortization of premiums and accretion of discounts on marketable debt securities

789

1,196

1,219

751

-9

-755

-1,294

-1,588

-1,724

-1,815

-1,912

-1,962

-2,002

-2,004

0

0

0

-

-

-

-

Depreciation and amortization

7,580

7,200

6,558

5,633

4,780

4,000

3,408

3,173

2,980

2,700

2,243

1,697

1,050

544

301

169

128

80

0

0

0

Net realized gains on sales and maturities of marketable securities

0

-

-

-

-

-

-

-

-

479

0

0

0

-

-

-

-

-

-

-

-

Imputed interest income from licensing

3,186

2,951

2,675

2,068

8,204

8,946

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized losses on marketable equity securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency transaction gains

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Imputed interest on related party promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other non-cash adjustments

34

-268

-359

-443

-331

-14

-46

-46

-42

-73

0

0

0

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

14,957

8,622

34,488

27,101

-35,202

16,803

-7,397

-8,458

51,656

-561

236

-702

-1,763

-1,073

83

97

483

265

0

0

0

Prepaid expenses

1,130

973

844

2,578

1,857

400

3,083

1,258

2,824

3,559

1,054

952

654

755

771

310

1,137

992

0

0

0

Other current assets

3,037

499

-2,289

65

1,918

2,069

3,094

745

936

402

-610

-185

-378

159

0

0

0

-

-

-

-

Operating lease right-of-use assets

-2,561

-2,431

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

1,015

2,694

2,815

2,151

1,406

1,453

814

701

166

135

177

127

74

139

111

226

212

168

0

0

0

Accounts payable

4,275

1,528

4,965

1,896

-379

-218

1,635

-442

630

2,621

-2,267

1,979

2,836

186

3,868

935

-11

590

0

0

0

Accrued expenses and other current liabilities

6,001

6,882

6,134

4,059

4,160

7,582

1,886

4,494

4,307

1,897

2,731

860

743

3,873

6,054

4,136

2,815

2,221

0

0

0

Operating lease liabilities

-2,514

-2,255

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Advance payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-127

0

0

0

-

-

-

-

Other related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,761

0

0

0

Deferred rent

-

-

-

-

-

-32

-9

22

-15

-86

-143

587

780

1,277

0

0

0

-

-

-

-

Other liabilities

-1,035

-523

1,307

1,303

85

1,686

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-113,981

-107,705

-86,339

-76,743

17,217

104,648

94,962

97,383

17,623

-57,992

-64,589

-59,271

-58,152

-48,558

-32,578

-29,155

-28,727

-22,515

0

0

0

Cash flows from investing activities
Purchases of marketable debt securities

142,178

190,735

253,857

412,867

470,811

445,829

341,938

161,122

117,713

68,634

59,403

59,404

29,831

45,072

0

0

0

-

-

-

-

Maturities of marketable debt securities

263,736

289,994

281,658

252,366

247,389

179,749

139,109

110,859

79,249

70,224

81,680

74,465

72,980

72,586

0

0

0

-

-

-

-

Sales of marketable equity securities

0

-

-

-

-

-

-

-

-

780

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

13,895

11,720

15,578

16,271

13,389

13,278

10,490

7,568

6,575

7,160

9,494

11,267

10,662

8,149

3,842

1,698

832

522

0

0

0

Net cash provided by investing activities

120,807

93,559

12,223

-176,772

-236,811

-279,358

-213,319

-57,831

-45,039

-4,790

13,788

4,822

33,290

19,388

-142,388

-171,331

-174,433

-163,800

0

0

0

Proceeds from exercise of stock options

5,492

7,100

10,949

12,601

14,438

14,500

10,799

9,170

6,163

2,500

757

378

319

179

181

145

121

107

0

0

0

Proceeds from issuance of common stock under employee stock purchase plan

1,556

1,314

1,311

870

870

847

850

751

751

556

0

0

0

-

-

-

-

-

-

-

-

Proceeds from public offerings of common stock, net of underwriting discounts and commissions

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance costs for public offerings of common stock

-

-

-

-

-

-

-

-

-

445

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

7,010

8,376

12,115

202,596

204,404

204,443

200,896

9,688

17,241

84,598

82,802

82,240

71,621

119

-2,250

145,354

213,303

239,310

0

0

0

Net decrease in cash and cash equivalents and restricted cash

13,836

-5,770

-62,001

-50,919

-15,190

29,733

82,539

49,240

-10,175

21,816

32,001

27,791

46,759

-29,051

-177,216

-55,132

10,143

52,995

0

0

0

Supplemental cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

0

0

0

Supplemental disclosures of non-cash investing and financing activities
Additions to property and equipment through accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

1,181

1,878

1,023

453

96

0

0

0

Issuance costs for public offerings of common stock in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Conversion of related party promissory notes into Series C convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,389

0

0

0